Platform disease-modifying therapies (DMTs) — the interferon-betas, glatiramer acetate, teriflunomide, and dimethyl fumarate — were the foundation of MS treatment for over two decades and remain important options, particularly for relapsing-remitting MS (RRMS) with lower disease activity. These agents have well-characterized safety profiles, generally lower risk of infection and malignancy than high-efficacy therapies, and are still considered appropriate first-line for many patients. This page covers the platform DMTs in detail; for high-efficacy therapies, see the dedicated page.

Interferon-β Therapies

Mechanism

  • Type I interferon; pleiotropic immunomodulation.
  • Shifts T-helper response (Th2 over Th1), reduces matrix metalloproteinase, downregulates adhesion molecules, modulates B cell function.
  • Reduces relapses by ~30%, slows disability progression modestly.

Formulations

  • Interferon-β-1a (Avonex): IM weekly.
  • Interferon-β-1a (Rebif): SC three times weekly.
  • Interferon-β-1b (Betaseron, Extavia): SC every other day.
  • Peg-interferon-β-1a (Plegridy): SC every 2 weeks (or IM).

Side Effects

  • Flu-like symptoms (mainstay; pre-medication helpful — acetaminophen, ibuprofen).
  • Injection site reactions, lipoatrophy with chronic SC injections.
  • Liver enzyme elevation; monitor LFTs.
  • Cytopenia, particularly lymphopenia.
  • Depression: warning; assess and monitor.
  • Neutralizing antibodies can reduce efficacy (uncommon in modern formulations).
  • Pregnancy: class C historically; emerging data suggests low teratogenic risk.

Place in Therapy

  • Mild RRMS, treatment-naive patient with low disease burden.
  • Patients preferring injectable over oral.
  • Pregnancy planning (relatively safer profile than many alternatives).
  • Less commonly chosen as first-line now in favor of oral or high-efficacy options.

Glatiramer Acetate (Copaxone, Glatopa)

Mechanism

  • Random copolymer of amino acids (alanine, lysine, glutamic acid, tyrosine); mimics myelin basic protein.
  • Induces glatiramer-specific T regulatory cells; modulates Th2 response.
  • Anti-inflammatory; neuroprotective hypothesis.

Formulations

  • 20 mg SC daily, or 40 mg SC three times weekly.
  • Generic glatiramer acetate (Glatopa) available.

Side Effects

  • Injection site reactions, panic-like immediate post-injection reaction (chest tightness, flush, dyspnea — transient, no long-term sequelae).
  • Lipoatrophy with chronic use.
  • Minimal lab abnormalities.

Place in Therapy

  • Treatment-naive RRMS.
  • Pregnancy: lowest known teratogenic risk of all DMTs; often continued through pregnancy.
  • Less effective than high-efficacy options but well-tolerated.

Teriflunomide (Aubagio)

Mechanism

  • Active metabolite of leflunomide.
  • Inhibits dihydroorotate dehydrogenase (DHODH) → blocks de novo pyrimidine synthesis in rapidly dividing lymphocytes.
  • Modest immunomodulation.

Dosing

  • 14 mg PO daily (7 mg available).

Side Effects

  • Hair thinning (common, often distressing).
  • GI: diarrhea, nausea.
  • Hepatic enzyme elevation.
  • Peripheral neuropathy (uncommon).
  • Hypertension.
  • Pregnancy: teratogenic (animal studies); washout protocol with cholestyramine or activated charcoal before conception.
  • Lymphopenia possible.

Place in Therapy

  • RRMS; alternative to interferon and glatiramer.
  • Once-daily oral convenience.
  • Avoid in women of childbearing age without effective contraception or planning washout.

Dimethyl Fumarate (Tecfidera) and Related Fumarates

Mechanism

  • Activates Nrf2 (nuclear factor-erythroid 2-related factor 2) → antioxidant response.
  • Anti-inflammatory; reduces NF-κB signaling.
  • Lymphocyte reduction (sometimes significant).

Dosing

  • 240 mg PO BID (oral).
  • Diroximel fumarate (Vumerity): prodrug; less GI side effects.
  • Monomethyl fumarate (Bafiertam): active metabolite; alternative.

Side Effects

  • Flushing (common, especially initial weeks; pretreat with aspirin or take with food).
  • GI: nausea, diarrhea, abdominal pain.
  • Lymphopenia (substantial in some; CD4 counts <500 require attention).
  • PML (progressive multifocal leukoencephalopathy): rare, reported in patients with prolonged lymphopenia; JCV antibody-positive at higher risk.
  • Liver enzyme elevation.
  • Pregnancy: limited data; generally avoid.

Place in Therapy

  • RRMS first-line oral option.
  • Tolerability much improved with diroximel fumarate.
  • Monitor CBC for lymphopenia.

S1P Receptor Modulators

Sphingosine-1-phosphate receptor modulators sequester lymphocytes in lymph nodes:

Fingolimod (Gilenya)

  • Mechanism: non-selective S1P receptor modulator.
  • Dose: 0.5 mg PO daily.
  • First-dose monitoring: bradycardia, AV block — observe 6 hours after first dose.
  • Side effects: bradycardia, hypertension, lymphopenia, macular edema, hepatic enzyme elevation, varicella reactivation, basal cell carcinoma risk.
  • Pregnancy: contraindicated.
  • Discontinuation rebound: severe disease activity possible (consider gradual switch to other DMT).

Ozanimod (Zeposia)

  • S1P1 and S1P5 selective.
  • Better cardiac safety profile; less first-dose monitoring needed.
  • Dose: gradual up-titration to 0.92 mg daily.
  • Also approved for ulcerative colitis.

Ponesimod (Ponvory)

  • S1P1 selective.
  • Daily dosing with up-titration.
  • Similar efficacy to teriflunomide in OPTIMUM trial.
  • Better cardiac profile than fingolimod.

Siponimod (Mayzent)

  • S1P1/S1P5 selective.
  • For SPMS (active disease).
  • Genotyping for CYP2C9: dose adjustment if poor metabolizer.

Switching Between DMTs

  • Direct switching often possible.
  • Washout periods for specific transitions (e.g., fingolimod → natalizumab consider longer to avoid PML risk).
  • Teriflunomide washout: cholestyramine if needed for rapid clearance.
  • JCV status: relevant for transitions to/from natalizumab.
  • Risk-benefit assessment by clinical scenario.

DMT Selection Framework

Active RRMS (relapses, MRI activity)

  • Increasingly favor high-efficacy DMT first-line.
  • Platform DMT if: mild disease, patient preference, pregnancy planning, financial.

Suboptimal Response to Platform DMT

  • Escalate to higher-efficacy: natalizumab, ocrelizumab, ofatumumab, fingolimod/ozanimod/ponesimod, cladribine.

SPMS

  • Active SPMS (continued relapses or new lesions): consider siponimod, ocrelizumab.
  • Non-active SPMS: progressive disability primarily; DMTs less effective; consider trial discontinuation.

PPMS

  • Ocrelizumab: FDA-approved; only DMT specifically approved for PPMS.

Pregnancy and DMTs

  • Glatiramer acetate: lowest known teratogenic risk; often continued through pregnancy.
  • Interferon-β: relatively safe; emerging data favorable.
  • Dimethyl fumarate, ozanimod: limited data; usually held.
  • Fingolimod, ozanimod, ponesimod: contraindicated.
  • Teriflunomide: teratogenic; washout protocol.
  • Natalizumab: rebound risk if discontinued; some specialists continue through 2nd trimester.
  • Cladribine: 6 months conception planning.
  • B-cell depleters (ocrelizumab, ofatumumab): 6-12 months before conception; limited fetal data.
  • Breastfeeding: many DMTs incompatible; glatiramer acetate and interferon-β acceptable.

Monitoring for DMTs

  • Baseline: CBC, CMP, LFTs, TSH, vitamin D, hep B/C, HIV, TB, JCV antibody, MRI brain (and cord if symptomatic).
  • Periodic: CBC, LFTs, MRI brain (annual or more frequent depending on therapy).
  • JCV antibody titer for natalizumab patients.
  • For fingolimod: ECG, ophtho.
  • For B-cell depleters: IgG/IgA levels at baseline + periodic.
  • Vaccinations: live vaccines avoided on most DMTs; flu and COVID vaccines important; pneumococcal, shingles (RZV inactivated) for many.

🔍 Did You Know?

The choice of “escalation” vs “induction” approach in MS treatment has been the central strategic debate in MS therapy for the past decade, and recent evidence has tilted heavily toward early high-efficacy treatment. The traditional “escalation” approach starts with platform DMTs and escalates to higher-efficacy agents only with breakthrough disease — minimizing exposure to risks but accepting some disease accumulation. The “induction” or “early high-efficacy” approach starts with potent therapy upfront — accepting some short-term risks for better long-term disease control. Observational studies and registry data increasingly support early high-efficacy treatment in relapsing MS — with associations including fewer relapses, less disability progression, and less brain atrophy. Randomized strategy trials such as TREAT-MS were designed to test this question prospectively; published TREAT-MS material so far is the trial design and baseline characteristics, not outcome data. Practice has shifted toward earlier high-efficacy therapy on the strength of observational evidence and biological rationale, with the awareness that randomized confirmation is still maturing. The implications: for newly diagnosed RRMS patients, many MS centers now offer high-efficacy first-line (ocrelizumab, ofatumumab, natalizumab) as the default for highly active disease, reserving platform DMTs for very mild disease or patient preference. For the practicing neurologist, this shift is reshaping the conversation with newly diagnosed patients — the question is less “which DMT” and more “how aggressive should we be.” The lesson generalizes: treatment philosophy in chronic neurologic disease is increasingly evidence-driven toward early intervention, with the recognition that brain tissue lost cannot be recovered. The same principle applies to AD (early anti-amyloid therapy) and other progressive conditions.

Pitfalls and Pearls

  • Interferon-β: pleiotropic; ~30% relapse reduction; flu-like; depression.
  • Glatiramer acetate: SC; lowest teratogenic risk; good for pregnancy planning.
  • Teriflunomide: oral; hair thinning; teratogenic (washout protocol).
  • Dimethyl fumarate: oral; flushing; lymphopenia (monitor); rare PML.
  • Diroximel fumarate: better tolerated than dimethyl fumarate.
  • Fingolimod: first oral S1P modulator; first-dose cardiac monitoring; rebound on discontinuation.
  • Ozanimod, ponesimod: better cardiac profile; selective S1P modulation.
  • Siponimod: SPMS; CYP2C9 genotyping.
  • JCV antibody: monitor for PML risk on natalizumab, fingolimod, dimethyl fumarate.
  • Pregnancy: glatiramer acetate and interferon-β safest; many DMTs contraindicated.
  • Live vaccines: avoid on DMTs; complete before initiation when possible.
  • Early high-efficacy DMT: trending in modern MS care for active RRMS.
  • Ocrelizumab: only FDA-approved DMT for PPMS.
  • SPMS: siponimod, ocrelizumab for active disease.
  • Rebound disease: warning when discontinuing certain DMTs (fingolimod, natalizumab).

References

  1. Wingerchuk DM, Carter JL. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Mayo Clin Proc. 2014;89(2):225-240.
  2. Ontaneda D, Tallantyre EC, Kalincik T, et al. Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis. Lancet Neurol. 2019;18(10):973-980.
  3. Newsome SD, Cohen JA, Ontaneda D, et al. The TRaditional versus Early Aggressive Therapy for Multiple Sclerosis (TREAT-MS) trial: design and baseline characteristics of participants. Mult Scler J. 2024 (online ahead of print).
  4. Hauser SL, Cree BAC. Treatment of multiple sclerosis: a review. Am J Med. 2020;133(12):1380-1390.e2.
  5. Coyle PK, Hartung HP. Use of interferon beta in pregnancy and lactation: an updated review. Mult Scler J. 2020;26(13):1772-1787.
  6. Comi G, Bar-Or A, Lassmann H, et al. Role of B cells in multiple sclerosis and related disorders. Ann Neurol. 2021;89(1):13-23.